Citations

Showing 10 of 108152 citations.

Expanding Spectrum of Desmin-Related Myopathy, Long-term Follow-up, and Cardiac Transplantation
Shelly, Shahar , Pereira, Naveen L. , Engel, Andrew G. , Johnson, Jonathan N. , Selcen, Duygu , Talha, Niaz, Shahar, Shelly , Niaz, Talha

Mayo Clinic

Neurology | July 27, 2021 | Volume: 97 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000012542 | PMID 34315782 Get It

Guidelines for Conducting Ethical Artificial Intelligence Research in Neurology
Chiong, Winston , Goldenholz, Daniel M. , Chiang, Sharon, Picard, Rosalind W, Moss, Robert, Goldenholz, Daniel M , Chiang, Sharon , Picard, Rosalind W. , MOSS, ROBERT E. , Worrell, Gregory A. , Rao, Vikram R.

Mayo Clinic

Neurology | July 27, 2021 | Volume: 97 | Issue: 13 | Pages: 632-640

10.1212/wnl.0000000000012570 | PMID 34315785 Get It

Surgical Treatment for Intrahepatic, Peri-Hilar, and Distal Cholangiocarcinoma: 20-Single Institutional Year Experience
Istanbouli, Ayah, Almerey, Tariq , Li, Zhuo , Li, Zhuo , Patel, Shreya , Patel, Shreya G. , Stauffer, John

Mayo Clinic

The American Surgeon™ | July 27, 2021 | Volume: 89 | Issue: 4 | Pages: 621-631

10.1177/00031348211034751 | PMID 34314644 Get It

Background Surgical resection is the curative treatment for all subtypes of cholangiocarcinoma (CCA), including intrahepatic, hilar/peri-hilar, and distal. This study evaluates patients with CCA who underwent surgery and determines factors that impact their survival. Methods A retrospective cohort study was performed for patients who underwent surgical resection for CCA at our institution from 1995 to 2016. Demographics, operative variables between CCA tumors, and postoperative complications were analyzed. Predictors of overall and recurrence-free survival were determined via statistical analysis. Results A total of 170 patients with a mean age of 61 years old underwent surgical resection of intrahepatic (n = 64, 37.6%), hilar/peri-hilar (n = 75, 44.1%), and distal (n = 31, 18.2%) CCA. Operations performed included liver resections (n = 83, 48.8%), liver transplants (n = 56, 32.9%), and pancreaticoduodenectomies (n = 31, 18.2%). The overall survival rate at 1, 5, and 10 years was 81.1%, 32.4%, and 17.2%, respectively. Low pathological stage and negative resection margins were associated with lower recurrence and higher survival rates. Tumor location and the type of operation performed were not predictive of recurrence or OS in this cohort. Discussion This study shows that definitive surgical resection with negative margins can result in long-term survival even at 10 years. Small tumor size and low pathological stage are predictive of higher survival rates post-surgery, emphasizing the importance of early diagnosis and appropriate surgical treatment in achieving positive outcomes.
Efficacy of Osimertinib Plus Bevacizumab In Glioblastoma Patients With Simultaneous EGFR Amplification And EGFRvIII Mutation
Jaramillo-Velásquez, Daniel , Cardona, Andrés F. , Ruíz-Patiño, Alejandro , Polo, Carolina , Jiménez, Enrique, Hakim, Fernando, Gómez, Diego F. , Ramón, Juan Fernando, Cifuentes, Hernando, Mejía, Juan Armando , Salguero, Fernando, Muñoz, Álvaro , Bermúdez, Sonia , Useche, Nicolás, Pineda, Diego, Ricaurte, Luisa , Zatarain-Barrón, Zyanya Lucía , Rodríguez, July, Ávila, Jenny , Rojas, Leonardo , Jaller, Elvira , Santoyo, Nicolás, Cardona, Andrés F , Rojas, Leonardo , Polo, Carolina, Ordóñez‐Reyes, Camila , Sotelo, Carolina , García-Robledo, Juan Esteban , Rolfo, Christian , Rosell, Rafael , Arrieta, Óscar

Mayo Clinic

No container title available | July 27, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-698468/v1 Get It

Abstract Background: Amplification of EGFR and its active mutant EGFRvIII are common in glioblastoma (GB). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has shown limited efficacy. To improve the likelihood of effectiveness, we targeted adult patients with recurrent GB enriched for simultaneous EGFR amplification and EGFRvIII mutation, with osimertinib/bevacizumab at doses described for non-small cell lung cancer (NSCLC). Methods: We retrospectively explored whether previously described EGFRvIII mutation in association with EGFR gene amplification could predict response to osimertinib/bevacizumab combination in a subset of 15 patients treated at recurrence. The resistance pattern in a subgroup of subjects is described using a commercial NGS panel in liquid biopsy.Results: There were ten males (66.7%), and the median patient’s age was 56 years (range 38-70 years). After their initial diagnosis, 12 patients underwent partial (26.7%) or total resection (53.3%). Subsequently, all cases received IMRT and concurrent and adjuvant temozolomide (TMZ; the median number of cycles 9, range 6-12). The median follow-up after recurrence was 17.1 months (95% CI 12.3-22.6). All patients received osimertinib/bevacizumab as a second-line intervention with a median progression-free survival (PFS) of 5.1 months (95% CI 2.8-7.3) and overall survival (OS) of 9.0 months (95% CI 3.9-14.0). The PFS6 was 46.7%, and the overall response rate (ORR) was 13.3%. After exposure to the osimertinib/bevacizumab combination, the main secondary alterations were MET amplification, STAT3, IGF1R, PTEN, and PDGFR.Conclusions: While the osimertinib/bevacizumab combination was marginally effective in most GB patients with simultaneous EGFR amplification plus EGFRvIII mutation, a subgroup experienced a long-lasting meaningful benefit. The findings of this brief cohort justify the continuation of the research in a clinical trial. The pattern of resistance after exposure to osimertinib/bevacizumab includes known mechanisms in the regulation of EGFR, findings that contribute to the understanding and targeting in a stepwise rational this pathway.
Relative Age Effect on Problematic Alcohol Use in Adolescents
Markota, Matej , Bieber, Ewa D. , Kirchoff, Robert W. , Croarkin, Paul E. , Kirchoff, Robert W , Bobo, William V. , Croarkin, Paul E , Coombes, Brandon J.

Mayo Clinic

Journal of Child and Adolescent Psychopharmacology | July 27, 2021 | Volume: 31 | Issue: 10 | Pages: 692-696

10.1089/cap.2021.0033 | PMID 34314608 Get It

The Relationship Between Presurgical Pain and Early Postbariatric Surgery Outcomes
Pudalov, Lauren R. , Martin‐Fernandez, Katy W. , Krause, Steven J., Heinberg, Leslie J.

Mayo Clinic

Bariatric Surgical Practice and Patient Care | July 27, 2021 | Volume: 17 | Issue: 2 | Pages: 73-78

10.1089/bari.2021.0043 Get It

Background: Individuals with obesity frequently contend with pain, but few studies address the clinical impact of comorbidity within this population. This study compared the early weight loss outcomes and complications of bariatric surgery for participants with and without presurgical pain. Methods: A retrospective analysis of data stored in a registry of patients who had undergone bariatric surgery was conducted. Patients completed a routine preoperative psychological and medical evaluation. Participants were grouped based upon the presence of at least one pain condition and/or pain site: pain ( n = 184) or no pain ( n = 30). Participants completed questionnaires regarding 21 psychological and 17 medical complications and reported their weights at their 1- and 3-month postoperative psychological appointments. Results: The majority of the final sample ( n = 214) identified as 69% female and 66% Caucasian. Contrary to the hypothesis, results indicated no significant mean differences in 1- and 3-month postoperative medical and psychological complications, or percentage excess and total weight loss between the groups. Conclusions: In the early postoperative period, participants with preoperative pain and comorbid obesity lose weight and experience complications to a degree comparable with participants without preoperative pain. Implications for clinical interventions and future research are discussed.
Efficiency in DIEP Flap Breast Reconstruction: The Real Benefit of Computed Tomographic Angiography Imaging
Guliyeva, Günel , Huayllani, María T. , Forte, Antonio J. , Forte, Antonio Jorge , Ávila, Francisco R. , Torres‐Guzman, Ricardo A.

Mayo Clinic

Plastic & Reconstructive Surgery | July 27, 2021 | Volume: 148 | Issue: 3 | Pages: 487e-488e

10.1097/prs.0000000000008234 | PMID 34313650 Get It

Evaluating consumer and clinical sleep technologies: an American Academy of Sleep Medicine update
Schutte-Rodin, Sharon, Deak, Maryann C., Khosla, Seema, Goldstein, Cathy , Yurcheshen, Michael , Chiang, Ambrose , Gault, Dominic, Kern, Joseph, O’Hearn, Daniel J. , Ryals, Scott, Verma, Nitun, Kirsch, Douglas B. , Baron, Kelly Glazer , Holfinger, Steven , Miller, Jennifer N. , Patel, Ruchir, Bhargava, Sumit, Ramar, Kannan , Holfinger, Steven J

Mayo Clinic

Journal of Clinical Sleep Medicine | July 27, 2021 | Volume: 17 | Issue: 11 | Pages: 2275-2282

10.5664/jcsm.9580 | PMID 34314344 Get It

Addressing a Missing Link in Emergency Preparedness: New Insights on the Ethics of Care in Contingency Conditions from the Minnesota COVID Ethics Collaborative
Wu, Joel T., DeBruin, Debra, Wolf, Susan M. , Klemond, Thomas, DeMartino, Erin S.

Mayo Clinic

The American Journal of Bioethics | July 27, 2021 | Volume: 21 | Issue: 8 | Pages: 17-19

10.1080/15265161.2021.1939809 | PMID 34313570 Get It

Electrogram‐guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes
Ezzeddine, Fatima M. , Kapa, Suraj , Rosenbaum, Andrew , Blauwet, Lori A., Deshmukh, Abhishek , AbouEzzeddine, Omar F. , Maleszewski, Joseph J. , Asirvatham, Samuel J. , Bois, John P. , Schirger, John A., Siontis, Konstantinos C. , Blauwet, Lori, Deshmukh, Abhishek J , Siontis, Konstantinos C , Asirvatham, Samuel J , Kapa, Suraj , Ezzeddine, Fatima , AbouEzzeddine, Omar F , Chareonthaitawee, Panithaya

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 27, 2021 | Volume: 32 | Issue: 9 | Pages: 2486-2495

10.1111/jce.15191 | PMID 34314091 Get It

AbstractObjectiveEndomyocardial biopsy (EMB) is a useful diagnostic tool though the yield may be limited in many myocardial diseases. Data on the diagnostic yield and prognostic significance of EMB guided by abnormal electrograms (EGM‐Bx) in suspected cardiac sarcoidosis (CS) are scarce.MethodsSeventy‐nine patients (mean age: 56 ± 12 years; 61% men) with suspected CS based on clinical and imaging features underwent right or left ventricular EGM‐Bx guided by electroanatomic mapping. Tissue samples were obtained from sites with abnormal EGMs and/or abnormal cardiac imaging. The diagnostic yield of EGM‐Bx was evaluated in reference to histopathologic analysis. Left ventricular assist device (LVAD) and transplantation‐free survival were compared between patients with positive and negative EGM‐Bx for CS.ResultsA total of 254 samples were obtained from abnormal EGM sites, and 126 samples from normal EGM sites guided by pre‐procedure imaging findings. Abnormal histopathology was noted in 65 (26%) and 10 (8%) samples from abnormal and normal EGM sites, respectively. Histopathology confirmed CS in 16 (20%) patients, while an alternative tissue diagnosis emerged in 10 (13%) patients. Abnormal EGMs at the biopsy site had sensitivity 89% and specificity 33% for a histopathologic diagnosis of CS. LVAD and transplantation‐free survival were not significantly associated with the EGM‐Bx result (log‐rank p = .91).ConclusionIn patients with suspected CS, abnormal EGM‐Bx has high sensitivity and low specificity for establishing a definite CS diagnosis. Consideration of substrate abnormalities apparent on preprocedural imaging as an adjunct for selection of biopsy sites may further improve EGM‐Bx yield.